SYS-CON MEDIA Authors: Elizabeth White, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

SkinCeuticals Announces Agenda For American Academy Of Dermatology's 2014 Annual Meeting

The Antioxidant Authority Will Unveil a Groundbreaking New Product and Present a Record-Breaking 13 Posters to Dermatologists

NEW YORK, March 14, 2014 /PRNewswire/ -- From March 21-25, more than 11,000 dermatologists and medical personnel from 97 countries will converge in Denver, Colorado for the American Academy of Dermatology's (AAD) 2014 Annual Meeting, and SkinCeuticals will have a strong presence. In addition to the presentation of 13 peer-reviewed posters and a booth (#3800) staffed with SkinCeuticals executives and skincare experts for the duration of the meeting, the brand's 2014 AAD agenda also includes lectures at the booth by David McDaniel, MD (March 21, 1pm) and Patti Farris, MD (March 22, 10:30am; March 23, 10:30am), who will both speak about breakthrough research on the antioxidant resveratrol and its anti-aging benefits.

These discussions coincide with the launch of SkinCeuticals latest groundbreaking product, Resveratrol B E, which is the first topical antioxidant designed for nighttime use. A polyphenol antioxidant that is also known as the "longevity molecule," resveratrol is the latest addition to SkinCeuticals ingredient portfolio. "Resveratrol B E is a potent antioxidant night concentrate that boosts skin's internal defense system to help repair and prevent accumulated damage," says Marc Toulemonde, SkinCeuticals Global General Manager. "By maximizing skin's nighttime reconstruction potential, Resveratrol B E offers a comprehensive approach to preventing and repairing visible signs of skin aging through three modes of action. It neutralizes age-accelerating internal free radicals, promotes skin's natural repair to diminish the signs of accumulated damage and strengthens skin to resist new damage." 

As with all SkinCeuticals products, Resveratrol B E has been subjected to rigorous clinical testing, including a trial of 55 women with mild to moderate hyperpigmentation, skin laxity, and lines and wrinkles. After 12 weeks of use, Resveratrol B E significantly improved skin radiance, firmness, thickness, elasticity, density, and smoothness.

Ultrasound measurement was used to visualize the effects of Resveratrol B E within the skin. After 12 weeks of use, underlying skin repair prompted an 18.9% increase in skin density.

Demonstrating a commitment to providing advanced skincare backed by science, SkinCeuticals will share clinical evidence from research conducted on the brand's star technologies through 13 poster abstracts accepted by the AAD, the highest number in the company's history. Resveratrol B E, C E Ferulic, Advanced Pigment Corrector, Body Tightening Concentrate, Body Retexturing Treatment, Retinol 0.3%, and Redness Neutralizer are among the SkinCeuticals products and technologies that will be presented.

Physicians can visit booth #3800 to speak with SkinCeuticals executives and skincare experts about the latest research, the launch of Resveratrol B E, and other SkinCeuticals products and technologies.

Journalists who would like to learn more about the poster presentations and SkinCeuticals brand information can contact Genevieve Lee Aronson at Alison Brod Public Relations (212.230.1800, [email protected]) or Jacqueline Porter at SkinCeuticals (212.984.4539, [email protected]).

ABOUT SKINCEUTICALS
Founded in Dallas, TX in 1997, SkinCeuticals discovers, develops and delivers an advanced line of scientifically backed cosmeceutical treatments.  As leaders in antioxidant and sun protection technology, SkinCeuticals products have been shown to dramatically improve skin health by protecting skin from environmental damage and visibly improving skin clarity, tone, and texture to minimize the appearance of fine lines and wrinkles. For more information, visit www.skinceuticals.com.

SOURCE SkinCeuticals

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.